Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen

Nephrology

Volumn 15, Issue 6, 2010, Pages 653-658

  Yilmaz, Mumtaz ^a   Nart, Ahmet ^b   Sen, Sait ^b   Tasli, Funda ^c   Uslu, Adam ^b   Hur, Ender ^a   Ozkahya, Mehmet ^a   Hoscoskun, Cuneyt ^c   Toz, Huseyin ^a  

^a EGE UNIVERSITY   (Turkey)

^b Ege University   (Norway)

^c Izmir Research and Training Hospital   (Turkey)

Author keywords

graft fibrosis; kidney transplantation; mtor inhibitor

Indexed keywords

BASILIXIMAB; EVEROLIMUS; MEPREDNISONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; ATROPHY; BIOPSY; CHI-SQUARE DISTRIBUTION; DELAYED GRAFT FUNCTION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FIBROSIS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 77956222223     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01365.x     Document Type: Article

References (28)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 2004 3 : 378 383.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 2000 342 : 605 612.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003 349 : 2326 2333.
4. Yilmaz S, McLaughlin K, Paavonen T et al. Clinical predictors of renal allograft histopathology: a comparative study of single-lesion histology versus a composite, quantitative scoring system. Transplantation 2007 83 : 671 676.
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004 78 : 434 441.
6. Ortiz F, Paavonen T, Törnroth T et al. Predictors of renal allograft histologic damage progression. J. Am. Soc. Nephrol. 2005 16 : 817 824.
7. Cosio FG, Grande JP, Larson TS et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am. J. Transplant. 2005 5 : 1130 1136.
8. Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr. Opin. Organ Transplant. 2008 13 : 614 621.
9. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006 81 : 643 654.
10. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998 66 : 1736 1740.
11. Flechner SM, Goldfarb D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007 83 : 883 892.
12. Ekberg H, Tedesco-Silva H, Demirbas A et al. ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007 357 : 2562 2575.
13. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin. J. Am. Soc. Nephrol. 2007 2 : 326 333.
14. Paul LC, Sijpkens YW. Renal transplant protocol biopsies: a surrogate biomarker for late graft loss. Transplantation 2000 69 : 1771 1772.
15. Serón D. Interstitial fibrosis and tubular atrophy in renal allograft protocol biopsies as a surrogate of graft survival. Transplant. Proc. 2009 41 : 769 770.
16. Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999 55 : 713 723.
17. Solez K, Colvin RB, Racusen LC. Banff 07 classification of renal allograft pathology: updates and future directions. Am. J. Transplant. 2008 8 : 753 760.
18. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am. J. Transplant. 2003 3 (Suppl 4 114 125.
19. Dean PG, Grande JP, Sethi S et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008 85 : 1212 1215.
20. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomised trial comparing sirolimus and tacrolimus. Am. J. Transplant. 2006 6 : 514 522.
21. Kamar N, Van TT, Ribes D et al. Renal function and histology in kidney transplant patients receiving tacrolimus and sirolimus or mycophenolate mofetil. Exp. Clin. Transplant. 2006 4 : 532 536.
22. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transplant. 2004 4 : 1776 1785.
23. Mota A, Arias M, Taskinen EI et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am. J. Transplant. 2004 4 : 953 961.
24. McTaggart RA, Gottlieb D, Brooks J et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am. J. Transplant. 2003 3 : 416 423.
25. Uslu A, Nart A, Taşli FA et al. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation. Nephrology 2008 13 : 80 6.
26. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003 76 : 1594 1599.
27. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr. Opin. Nephrol. Hypertens. 2002 11 : 301 308.
28. Pontrelli P, Rossini M, Infante B et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008 85 : 125 134.